- 抑制劑
- 研究領(lǐng)域
- PI3K/Akt/mTOR信號(hào)通路
- 表觀遺傳
- 甲基化
- 免疫&炎癥
- 酪氨酸蛋白激酶
- 血管生成
- 凋亡
- 自噬
- 內(nèi)質(zhì)網(wǎng)應(yīng)激&UPR響應(yīng)
- JAK/STAT信號(hào)通路
- MAPK信號(hào)通路
- 細(xì)胞骨架
- 細(xì)胞周期
- TGF-beta/Smad信號(hào)通路
- DNA損傷/DNA修復(fù)
- 化合物庫(kù)
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲(chǔ)液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 動(dòng)物實(shí)驗(yàn)
- 鼠尾直接PCR試劑盒(快速基因型鑒定)
- 小鼠CD3+ T細(xì)胞分選試劑盒
- 小鼠CD4+ T細(xì)胞分選試劑盒
- 小鼠CD8+ T細(xì)胞分選試劑盒
- 新產(chǎn)品
- 聯(lián)系我們
Melphalan
別名: Alkeran, Sarcolysin, L-PAM 中文名稱：米爾法蘭
Melphalan (Alkeran, Sarcolysin, L-PAM)是氮芥的苯丙氨酸衍生物，具有抗腫瘤活性。此產(chǎn)品為危化品（急性毒性/易燃/皮膚腐蝕），請(qǐng)?jiān)诖┐鞣雷o(hù)面罩、防護(hù)手套和防護(hù)服后使用。 已取得危險(xiǎn)化學(xué)品經(jīng)營(yíng)許可
Melphalan Chemical Structure
CAS: 148-82-3
產(chǎn)品質(zhì)控
批次：
純度：
99.47%
99.47
Melphalan相關(guān)產(chǎn)品
| 相關(guān)靶點(diǎn) | AGT | 點(diǎn)擊展開(kāi) |
|---|---|---|
| 相關(guān)產(chǎn)品 | Lomeguatrib Lobaplatin (D-19466) Methyl methanesulfonate | 點(diǎn)擊展開(kāi) |
| 相關(guān)化合物庫(kù) | FDA藥物庫(kù) 天然產(chǎn)物庫(kù) 凋亡分子化合物庫(kù) DNA損傷/ DNA修復(fù)化合物庫(kù) 細(xì)胞周期化合物庫(kù) | 點(diǎn)擊展開(kāi) |
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類(lèi)型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息(PMID) |
|---|---|---|---|---|---|
| K562 | Cytotoxicity assay | 1 h | In vitro cytotoxic activity against human leukemic cell line K562 after incubation for 1 hour, IC50=30 μM | ||
| L1210 cell | Cytotoxicity assay | 72 h | Tested in vitro for the cytotoxicity as number of viable cells against L1210 cell line after 72 hr treatment at conc. of 10E-6, ID50=1.7 μM | ||
| LoVo cell | Growth inhibition assay | 144 hr | Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line, IC50=4.09 μM | ||
| MOLT3 cells | Function assay | 72 h | Antitumor activity against human MOLT3 cells in presence of Penicillin-G-amidase after 72 hrs by XTT assay, IC50=0.3 μM | ||
| RT4 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human RT4 cells after 96 hrs by microtiter assay, IC50=14.25 μM | ||
| RT112 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human RT112 cells after 96 hrs by microtiter assay, IC50=4.69 μM | ||
| 5637 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human 5637 cells after 96 hrs by microtiter assay, IC50=0.31 μM | ||
| KYSE70 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human KYSE70 cells after 96 hrs by microtiter assay, IC50=16.16 μM | ||
| KYSE510 | Cytotoxicity assay | 96 h | Cytotoxicity against human KYSE510 cells after 96 hrs by microtiter assay, IC50=8.18 Μm | ||
| KYSE520 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human KYSE520 cells after 96 hrs by microtiter assay, IC50=10.49 μM | ||
| YAPC cells | Cytotoxicity assay | 96 h | Cytotoxicity against human YAPC cells after 96 hrs by microtiter assay, IC50=5.95 μM | ||
| DAN-G cells | Cytotoxicity assay | 96 h | Cytotoxicity against human DAN-G cells after 96 hrs by microtiter assay, IC50=2.65 μM | ||
| SISO cells | Cytotoxicity assay | 96 h | Cytotoxicity against human SISO cells after 96 hrs by microtiter assay, IC50=1 μM | ||
| LCLC-103H cells | Cytotoxicity assay | 96 h | Cytotoxicity against human LCLC-103H cells after 96 hrs by microtiter assay, IC50=4 μM | ||
| MCF7 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human MCF7 cells after 96 hrs by microtiter assay, IC50=3.71 μM | ||
| A427 cells | Cytotoxicity assay | 96 h | Cytotoxicity against human A427 cells after 96 hrs by microtiter assay, IC50=5.13 μM | ||
| Caov3 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human Caov3 cells after 72 hrs by MTT assay | ||
| NSCLC cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells assessed as cell growth after 48 hrs by SRB assay, GI50=6.736083 μM | ||
| CNSC cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNSC cells assessed as cell growth after 48 hrs by SRB assay, GI50=7.58578 μM | ||
| mouse FM3A/0 cells | Proliferation assay | 48 hrs | Antiproliferative activity against mouse FM3A/0 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting, IC50=3.6 μM | ||
| CEM/0 cells | Proliferation assay | 48 hrs | Antiproliferative activity against human CEM/0 cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting, IC50=3.5 μM | ||
| HeLa cells | Proliferation assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by ZF-Coulter Counting, IC5=1.9 μM | ||
| SH-SY5Y cells | Cytotoxicity assay | 72 h | Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay, IC50=5.5 μM | ||
| U251 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human U251 cells after 5 days by MTT assay, IC50=3 μM | ||
| A549 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human A549 cells after 5 days by MTT assay, IC50=3 μM | ||
| PANC1 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human PANC1 cells after 5 days by MTT assay, IC50=3 μM | ||
| HT-29 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human HT-29 cells after 5 days by MTT assay, IC50=3 μM | ||
| DLD1 cells | Cytotoxicity assay | 5 days | Cytotoxicity against human DLD1 cells after 5 days by MTT assay, IC50=3 μM | ||
| HeLa cells | Cytotoxicity assay | 4 days | Cytotoxicity against human HeLa cells after 4 days by Coulter counter analysis, IC50=1.9 μM | ||
| FM3A cells | Cytotoxicity assay | 2 days | Cytotoxicity against mouse FM3A cells after 2 days by Coulter counter analysis, IC50=3.6 μM | ||
| HL-60(TB) cells | Function assay | 24 h | Antileukemic activity against human HL-60(TB) cells assessed as inhibition of tumor growth after 24 hrs, IC50=0.38 μM | ||
| SR cells | Function assay | 24 h | Antileukemic activity against human SR cells assessed as inhibition of tumor growth after 24 hrs, IC50=3.24 μM | ||
| L1210 cells | Proliferation assay | 2 days | Antiproliferative activity against mouse L1210 cells assessed as inhibition of cell proliferation incubated for 2 days by Coulter counter based assay, IC50=8.6 μM | ||
| FM3A cells | Proliferation assay | 2 days | Antiproliferative activity against mouse FM3A cells assessed as inhibition of cell proliferation incubated for 2 days by Coulter counter based assay, IC50=3.6 μM | ||
| CEM cells | Proliferation assay | 3 days | Antiproliferative activity against human CEM cells assessed as inhibition of cell proliferation incubated for 3 days by Coulter counter based assay, IC50=3.5 μM | ||
| HeLa cells | Proliferation assay | 4 days | Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 4 days by Coulter counter based assay, IC50=1.9 μM | ||
| C6 (Rat) Glioma cell lines | Cytotoxicity assay | The compound was tested for cytotoxicity against C6 (Rat) Glioma cell lines, IC50=11 μM | |||
| CEM T-lymphocytes | Cytotoxicity assay | Cytotoxicity against CEM T-lymphocytes, IC50=2.47 μM | |||
| D283 MR (human) Glioma cell lines | Cytotoxicity assay | The compound was tested for cytotoxicity against D283 MR (human) Glioma cell lines, IC50=16.3 μM | |||
| D283 (human) Glioma cell lines | Cytotoxicity assay | The compound was tested for cytotoxicity against D283 (human) Glioma cell lines, IC50=6.8 μM | |||
| D341 (human) Glioma cell lines | Cytotoxicity assay | The compound was tested for cytotoxicity against D341 (human) Glioma cell lines, IC50=12.4 μM | |||
| Jurkat T cells | Cytotoxicity assay | Inhibitory concentration against Human Jurkat T cells, IC50=2.2 μM | |||
| MCF-7 cells | Cytotoxicity assay | In vitro cytotoxicity activity against MCF-7, IC50=0.3 μM | |||
| Molt 4/C8 cells | Cytotoxicity assay | Cytotoxicity against human Molt 4/C8 cells, IC50=3.24 μM | |||
| P388 cells | Cytotoxicity assay | Cytotoxicity evaluated against P388 cells, IC50=0.22 μM | |||
| MCF-7 | Proliferation assay | Antiproliferative activity in MCF-7 human breast cancer cells, IC50=5.7 μM | |||
| C6 glioma cell line | Cytotoxicity assay | Cytotoxicity against rat C6 glioma cell line, IC50=12.6 μM | |||
| HCT116 cells | Cytotoxicity assay | Cytotoxicity against human HCT116 cells, IC50=30.2 μM | |||
| HCT15 cells | Cytotoxicity assay | Cytotoxicity against human HCT15 cells, IC50=36.3 μM | |||
| KM12 cells | Cytotoxicity assay | Cytotoxicity against human KM12 cells, IC50=43.7 μM | |||
| SW620 cells | Cytotoxicity assay | Cytotoxicity against human SW620 cells, IC50=38.9 Μm | |||
| HCC2998 cells | Cytotoxicity assay | Cytotoxicity against human HCC2998 cells, IC50=41.7 μM | |||
| SR cells | Cytotoxicity assay | Cytotoxicity against human SR cells, IC50=1.86 μM | |||
| HSC2 cells | Cytotoxicity assay | Cytotoxicity against HSC2 cells, CC50=35 μM | |||
| HL60 cells | Cytotoxicity assay | Cytotoxicity against human HL60 cells, CC50=6 μM | |||
| HepG2 cells | Growth inhibition assay | Growth inhibition of human HepG2 cells, GI50=17 μM | |||
| INA-6 cells | Cytotoxicity assay | Cytotoxicity against human INA-6 cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry, EC50=2 μM | |||
| PBMC cells | Cytotoxicity assay | Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry, EC50=3 μM | |||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Melphalan (Alkeran, Sarcolysin, L-PAM)是氮芥的苯丙氨酸衍生物，具有抗腫瘤活性。此產(chǎn)品為危化品（急性毒性/易燃/皮膚腐蝕），請(qǐng)?jiān)诖┐鞣雷o(hù)面罩、防護(hù)手套和防護(hù)服后使用。 |
|---|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | 將骨髓瘤細(xì)胞系RPMI 8226暴露于30分鐘的melphalan脈沖，melphalan作為DNA交聯(lián)劑，引起細(xì)胞周期進(jìn)展延遲[1]。Melphalan在體外細(xì)胞中結(jié)合DNA、RNA和蛋白。Melphalan在體外人類(lèi)細(xì)胞中誘導(dǎo)染色體畸變、姊妹染色單體互換、微核、HPRT基因的突變和DNA損傷。它還能誘導(dǎo)C3H 10T1/2和其他細(xì)胞的轉(zhuǎn)化。除此之外，melphalan在細(xì)菌和果蠅中誘導(dǎo)異倍體以及伴性隱性致死突變[3]。 | |||
|---|---|---|---|---|
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 在小鼠研究中，Melphalan常以口服、腹腔注射以及皮膚給藥途徑進(jìn)行給藥。在大鼠研究中為腹腔注射，在猴子中是口服給藥。在小鼠中，melphalan的處理會(huì)導(dǎo)致前胃乳頭瘤、淋巴肉瘤、皮膚和肺腫瘤。在大鼠中，melphalan的處理會(huì)導(dǎo)致乳腺腫瘤和腹膜肉瘤。在猴子中melphalan的處理結(jié)果目前還不確定[3]。 | |
|---|---|---|
| 動(dòng)物實(shí)驗(yàn) | Animal Models | Tg.AC 小鼠 |
| Dosages | 0.25, 1和4 mg/kg/每周 | |
| Administration | 皮膚局部給藥/口服 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06313502 | Not yet recruiting | Plasma Cell Disorder |
University of Arkansas|University of Iowa |
June 2024 | Phase 1 |
| NCT04455139 | Terminated | Eye Cancer Retinoblastoma |
Prof. Beck Popovic Maja|University of Lausanne Hospitals |
November 15 2021 | Phase 2 |
| NCT04945954 | Not yet recruiting | Hematopoietic Stem Cell Transplantation |
Seoul National University Hospital|National Institute of Food and Drug Safety Evaluation (Republic of Korea) |
June 2021 | Not Applicable |
|
化學(xué)信息&溶解度
| 分子量 | 305.20 | 分子式 | C13H18Cl2N2O2 |
| CAS號(hào) | 148-82-3 | SDF | Download Melphalan SDF |
| Smiles | C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl | ||
| 儲(chǔ)存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 3.5 mg/mL ( (11.46 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開(kāi)封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動(dòng)物體內(nèi)配方計(jì)算器 | |||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過(guò)程中的損耗，建議多配一只動(dòng)物的藥量）
mg/kg
g
μL
只
第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過(guò)該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問(wèn)題，均可以通過(guò)撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。
如果有其他問(wèn)題，請(qǐng)給我們留言。
* 必填項(xiàng)
Copyright 2013 Selleck中國(guó). All Rights Reserved.
滬ICP備13045345號(hào)-1滬公網(wǎng)安備 31011502012800號(hào)
